A Review of Adalimumab Biosimilars for the Treatment of Immune-Mediated Rheumatic Conditions

Authors: Ana Valido,1 Filipe C. Araújo,2 João Eurico Fonseca,1,3 João Gonçalves4

1. Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, Lisbon Academic Medical Centre, Lisbon, Portugal
2. Rheumatology and Osteoporosis Unit, Hospital de Sant'Ana, Parede, Portugal
3. Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
4. iMed - Research Institute for Medicines, Faculdade de Farmácia da Universidade de Lisboa, Lisbon, Portugal

*Correspondence to flipar@msn.com

Disclosure: Dr Fonseca has declared personal fees from Ache, Biogen, BMS, Janssen, Eli Lilly, Roche, Sanofi; grants from Amgen and Bial; grants and personal fees from AbbVie, MSD, Novartis, Pfizer; and grants from UCB, outside the submitted work.

Dr Araújo has received consultant and speaker fees from Pfizer, Biogen, MSD, and Novartis. Dr Goncalves has received fees from Pfizer, Merck, AbbVie, Roche, Celltrion, and Sandoz. Dr Valido has declared no conflicts of interest.

Received: 18.03.2019
Accepted: 28.05.2019

Keywords: Adalimumab, ankylosing spondylitis, biosimilar, immunogenicity, rheumatoid arthritis, switch.

Citation: EMJ Rheumatol. 2019;6[1]:122-133.

Abstract

Adalimumab is a recombinant fully human monoclonal antibody targeting soluble and transmembrane TNF alpha. It is approved for the treatment of immune-mediated rheumatic, gastroenterological, dermatological, and ophthalmological conditions and this therapeutic versatility has made it the top-selling drug worldwide since 2012. Not surprisingly, following the patent expiration of the originator drug, biopharmaceutical companies invested in the development of biosimilar versions of adalimumab and six have already received marketing authorisation: ABP 501, GP2017, and BI 695501 in Europe and in the USA (though the manufacturer of the latter requested authorisation withdrawal in Europe), and SB5, FKB327, and MSB11022 in Europe. This manuscript reviews published data on approved adalimumab biosimilars, including analytical and biofunctional results from preclinical assessments; pharmacokinetics after administration in healthy subjects (Phase I trials); and efficacy, safety, and immunogenicity from pivotal (Phase III) clinical trials. Data on switching from reference adalimumab to biosimilars, and predicted cost-savings from available budget impact models, will also be addressed.
Adalimumab is a recombinant fully human monoclonal antibody (IgG1 type) targeting soluble and transmembrane TNF. AbbVie’s bio-originator adalimumab, branded name Humira® (AbbVie, USA), is the top global selling drug since 2012 and it is approved for the treatment of immune-mediated inflammatory conditions of rheumatic, ophthalmological, dermatological, and gastroenterological nature. Adalimumab is indicated for rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis, juvenile idiopathic arthritis (polyarticular and enthesitis-related arthritis), psoriasis, hidradenitis suppurativa, adult and paediatric Crohn’s disease, ulcerative colitis, and adult non-infectious uveitis. In the European Union (EU), but not in the USA, adalimumab is also indicated for non-radiographic axial spondyloarthritis, paediatric psoriasis, paediatric hidradenitis suppurativa, and paediatric non-infectious uveitis. The approaching date of patent expiration, alongside the prospect of entering a several billion-dollar market, has led biopharmaceutical manufacturers to invest in the development of biosimilar versions of adalimumab. By the time this manuscript was elaborated, six biosimilars were given positive opinions by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA): ABP 501 (Amgen), GP2017 (Sandoz), BI 695501 (Boehringer-Ingelheim), and BL 695501 requested withdrawal of marketing authorisation in Europe due to unresolved patent litigation with AbbVie in the USA.

The current article performs a comprehensive review of adalimumab biosimilars approved in highly regulated markets, including available preclinical data, pharmacokinetics (PK), efficacy, safety, and immunogenicity assessments, and pharmacoeconomic considerations.

### Table 1: Adalimumab biosimilars already approved and currently being developed in highly regulated markets

<table>
<thead>
<tr>
<th>Approved adalimumab biosimilars</th>
<th>Adalimumab biosimilars in development</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABP 501 (Amgen) - USA and Europe</td>
<td>M923 (Momenta Pharmaceuticals)</td>
</tr>
<tr>
<td>GP2017 (Sandoz) - USA and Europe</td>
<td>CHS-1420 (Coherus Biosciences)</td>
</tr>
<tr>
<td>BI 695501 (Boehringer-Ingelheim) - USA and Europe*</td>
<td>PF-06410293 (Pfizer)</td>
</tr>
<tr>
<td>S85 (Biogen) - Europe</td>
<td>ONS-3010 (Oncobiologics)</td>
</tr>
<tr>
<td>FKB327 (Fujifilm Kyowa Kirin) - Europe</td>
<td>AVT02 (Alvovtech Swiss AG)</td>
</tr>
<tr>
<td>MSB11022 (Fresenius Kabi) - Europe</td>
<td>CT-P17 (Celltrion)</td>
</tr>
<tr>
<td>LBAL (LG Life Sciences)</td>
<td></td>
</tr>
</tbody>
</table>

*Marketing authorisation withdrawn by the manufacturer.
Adalimumab biosimilar candidates were tested against several batches of USA and Europe-sourced reference products for key quality attributes such as primary structure (molecular mass, protein sequence, and post-translational modifications), high-order (secondary and tertiary) structures, product-related and host-cell impurities, general properties, and product stability. State-of-the-art, sensitive, and orthogonal analytical methods were employed, many of them developed or adapted specifically for this purpose. Batches of biosimilar candidates were compared with reference products using pre-established similarity ranges or direct side-by-side comparisons.

After a thorough assessment of preclinical data within the marketing authorisation application, the regulatory agencies considered there was sufficient information to ensure a similar clinical performance in ABP 501, SB5, GP2017, BI 695501, FKB327, and MSB11022, despite some minor quality differences found in some of these candidates, which were duly justified and were not expected to impact PK, efficacy, or safety. For instance, SB5 had a slightly higher amount of free sulfhydryl groups, as well as charged N-glycans and acidic variants compared to reference adalimumab. FKB327, on the other hand, showed differences in the glycosylation profile, with higher mannose content. This difference led inclusively to further in vitro bioassay testing and PK data statistical reanalysis, before similarity was confirmed.

Due to the pleiotropic nature of TNF, all known adalimumab mechanisms of action with potential clinical relevance must be compared in vitro. Furthermore, biofunctional testing also demonstrates that differences in quality attributes, should they exist (for instance, post-translational modifications), do not impact in vitro biological activity. Biofunctional data provided by ABP 501, SB5, GP2017, BI 695501, FKB327, and MSB11022 manufacturers showed a high degree of similarity in both Fab and Fc-mediated functions, including, but not limited to, binding and neutralisation of soluble and transmembrane TNF; binding to FcRn, FcγRIa, FcγRIIa, and FcγRIIIa receptors; and antibody-dependent and complement-dependent cytotoxicity.

Although not mandatory, most of these biosimilar manufacturers provided PK and toxicology assessments in animal models in the data package presented to the regulatory agencies, once again demonstrating a high degree of similarity to reference products.

All biosimilar candidates demonstrated PK equivalence with EU and USA-sourced reference adalimumab in Phase I trials performed in healthy subjects, with the confidence intervals of the primary endpoints (area under the curve [AUC] and maximum drug concentration [Cmax]) falling within the prespecified range of 0.80–1.25 (Table 2). In accordance with regulatory requirements, Phase III trials were performed using a randomised, double-blind, parallel-group design. RA was chosen as the disease population in all but MSB11022, which was tested in patients with plaque-type psoriasis; ABP 501 and GP2017 also have available studies in this condition (Table 3). All biosimilar candidates confirmed similar efficacy, safety, and immunogenicity to reference adalimumab.

**Efficacy**

In Phase III trials, biosimilar candidates must demonstrate equivalence to their reference drug, in contrast with pivotal trials of bio-originators in which superiority over placebo is the endpoint. From a statistical point of view, this means that the confidence intervals of the primary efficacy endpoint(s) must be contained within prespecified equivalence margins that are calculated for each biosimilar drug based on historical data from the reference product and by comparison with prior study designs.

Primary efficacy endpoints were met in all Phase III trials in RA, namely similar American College of Rheumatology 20% (ACR20) improvement criteria responses at Week 24 between reference adalimumab and ABP 501, SB5, BI 695501, and FKB327, and similar mean change in disease activity score-28 including high-sensitivity C-reactive protein (DAS28-CRP) at Week 12 for GP2017 (Table 3). Noteworthy, ABP 501 presented statistically significant superiority over reference drug in ACR20 responses at Weeks 2 and 12, but not at other time points or secondary efficacy endpoints.
not considered by the regulatory agencies to compromise biosimilarity and was attributed to chance. Secondary efficacy endpoints, including ACR50/70 responses, European League Against Rheumatism (EULAR) criteria responses, and DAS28 variations and remission were also similar between reference drug and biosimilar candidates.\textsuperscript{18,22,24,26-28} Interestingly, in pivotal trials of adalimumab biosimilars, a slightly higher proportion of patients in both biosimilar and reference arms achieved the ACR20 primary endpoint compared to the active arm in pivotal trials of originator adalimumab, which may be attributed to different trial designs.\textsuperscript{32}

### Table 2: Phase I clinical trials for each approved adalimumab biosimilar.

<table>
<thead>
<tr>
<th>Biosimilar</th>
<th>Trial phase</th>
<th>Population</th>
<th>N</th>
<th>Primary endpoint</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABP 501</td>
<td>Phase I\textsuperscript{16}</td>
<td>Healthy subjects</td>
<td>203</td>
<td>PK bioequivalence of ABP 501 and USA and EU-ADL, as assessed by AUCinf and Cmax; equivalence margin 0.80–1.25</td>
<td><strong>EFFICACY:</strong> ABP 501/USA-ADL: AUCinf 1.11 (90% CI: 1.00–1.24); Cmax 1.04 (90% CI: 0.96–1.12); ABP 501/EU-ADL: AUCinf 1.04 (90% CI: 0.94–1.17); Cmax 0.96 (90% CI: 0.89–1.03); USA-ADL/EU-ADL: AUCinf 0.94 (90% CI: 0.84–1.04); Cmax 0.92 (90% CI: 0.860–0.994)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>SAFETY:</strong> Any TEAE ABP 501: 58.2%, USA-ADL: 47.8%, EU-ADL: 68.7%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Any serious AE ABP 501: 0.0%, USA-ADL: 0.0%, EU-ADL: 1.5%*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*Was considered unrelated to the study drug</td>
</tr>
<tr>
<td>SB5</td>
<td>Phase I\textsuperscript{17}</td>
<td>Healthy subjects</td>
<td>189</td>
<td>PK bioequivalence of SB5 and USA-ADL, USA-ADL as assessed by AUCinf, AUC last, and Cmax; equivalence margin 0.80–1.25</td>
<td><strong>EFFICACY:</strong> SB5/USA-ADL: AUCinf 1.001 (90% CI: 0.890–1.126); AUClast 1.025 (90% CI: 0.911–1.153); Cmax 0.972 (90% CI: 0.881–1.073) SB5/EU-ADL: AUCinf 0.990 (90% CI: 0.885–1.108); AUClast 1.027 (90% CI: 0.915–1.153); Cmax 0.957 (90% CI: 0.870–1.504) USA-ADL/EU-ADL: AUCinf 1.011 (90% CI: 0.904–1.131); AUClast 0.998 (90% CI: 0.887–1.122); Cmax 1.016 (90% CI: 0.920–1.121)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>SAFETY:</strong> Any TEAE SB5: 57.1%, USA-ADL: 61.9%, EU-ADL: 46.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Any serious AE SB5: 1.6%,* USA-ADL: 1.6%,* EU-ADL: 0.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*Were considered unrelated to the study drug</td>
</tr>
<tr>
<td>GP2017</td>
<td>Phase I\textsuperscript{18}</td>
<td>Healthy subjects</td>
<td>318</td>
<td>PK bioequivalence of GP2017 and USA-ADL, USA-ADL as assessed by AUCinf and Cmax; equivalence margin 0.80–1.25</td>
<td><strong>EFFICACY:</strong> GP2017/EU-ADA: AUCinf 1.04 (90% CI: 0.96–1.13); Cmax 1.05 (90% CI: 0.99–1.11) EU-ADA/USA-ADA: AUCinf 1.04 (90% CI: 0.96–1.13); Cmax 0.95 (90% CI: 0.90–1.01)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>SAFETY:</strong> Any TEAE GP2017: 62.7%, ADL: 73.9%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Any serious AE GP2017: 0.3%,* ADL: 0.3%†</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>†Was considered unrelated to the study drug</td>
</tr>
<tr>
<td>Biosimilar</td>
<td>Trial phase</td>
<td>Population</td>
<td>N</td>
<td>Primary endpoint</td>
<td>Results</td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
<td>------------</td>
<td>----</td>
<td>------------------</td>
<td>---------</td>
</tr>
<tr>
<td>BI 695501</td>
<td>Phase I (VOLTAIRE-PK)</td>
<td>Healthy subjects</td>
<td>327</td>
<td>PK bioequivalence of BI 695501 and USA and EU-ADL as assessed by AUCinf, AUClast, and Cmax; equivalence margin 0.80–1.25</td>
<td><strong>EFFICACY</strong>&lt;br&gt;Bi 695501/USA-ADL: AUCinf 108.6% (90% CI: 98.5–119.8%); AUClast 107.3% (90% CI: 98.5–117.0%); Cmax 100.9% (90% CI: 95.2–106.9%)&lt;br&gt;Bi 695501/EU-ADL: AUCinf 101.3% (90% CI: 92.5–111.0%); AUClast 99.9% (90% CI: 92.2–108.4%); Cmax 96.4% (90% CI: 91.1–102.0%)&lt;br&gt;USA/EU-ADL: AUCinf 94.0% (90% CI: 86.0–102.8%); AUClast 93.7% (90% CI: 86.8–101.1%); Cmax 95.9% (90% CI: 90.8–101.3%)&lt;br&gt;<strong>SAFETY</strong>&lt;br&gt;Any TEAE&lt;br&gt;Bi 695501: 19.4%, USA-ADL: 26.9%, EU-ADL: 25.9%&lt;br&gt;Any serious AE&lt;br&gt;Bi 695501: 2.8%, USA-ADL: 2.8%, EU-ADL: 1.9%&lt;br&gt;Of these, two serious AE (abdominal pain in the BI 695501 group and appendicitis in the USA-approved Humira group) were considered related to the study drug</td>
</tr>
<tr>
<td>FKB327</td>
<td>Phase I</td>
<td>Healthy subjects</td>
<td>180</td>
<td>PK bioequivalence of FKB327 and USA and EU-ADL as assessed by AUCinf and Cmax; equivalence margin 0.80–1.25</td>
<td><strong>EFFICACY</strong>&lt;br&gt;FKB327/USA-ADL: AUCinf 0.98 (90% CI: 0.88–1.10); AUClast 1.01 (90% CI: 0.91–1.12); Cmax 1.07 (90% CI: 0.98–1.17)&lt;br&gt;FKB327/EU-ADL: AUCinf 1.06 (90% CI: 0.94–1.18); AUClast 108 (90% CI: 0.97–1.20); Cmax 113 (90% CI: 1.03–1.23)&lt;br&gt;USA/EU-ADL: AUCinf 0.93 (90% CI: 0.83–1.04); AUClast 0.93 (90% CI: 0.84–1.03); Cmax 0.95 (90% CI: 0.87–1.04)&lt;br&gt;<strong>SAFETY</strong>&lt;br&gt;Any TEAE&lt;br&gt;FKB327: 58.3%, USA-ADL: 60.0%, EU-ADL: 65.0%&lt;br&gt;Any serious AE&lt;br&gt;FKB327: 1.7%,* USA-ADL: 1.7%,* EU-ADL: 0.0%&lt;br&gt;*Possibly related to the study drug</td>
</tr>
<tr>
<td>MSB11022</td>
<td>Phase I</td>
<td>Healthy subjects</td>
<td>213</td>
<td>PK bioequivalence of MSB11022 and USA-ADL and EU-ADL as assessed by Cmax, AUCinf, and AUClast; equivalence margin 0.80–1.25</td>
<td><strong>EFFICACY</strong>&lt;br&gt;MSB11022/USA-ADL: AUCinf 90.46% (90% CI: 81.29–100.67%); AUClast 96.03% (90% CI: 85.32–108.88%); Cmax 97.22% (90% CI: 89.27–105.88%)&lt;br&gt;MSB11022/EU-ADL: AUCinf 89.12 (90% CI: 80.14–99.10%); AUClast 91.53% (90% CI: 81.33–103.02%); Cmax 95.38% (90% CI: 87.58–103.87%)&lt;br&gt;USA/EU-ADL: AUCinf 98.52% (90% CI: 88.56–109.59%); AUClast 95.32% (90% CI: 84.72–107.25%); Cmax 98.10% (90% CI: 90.11–106.81%)&lt;br&gt;<strong>SAFETY</strong>&lt;br&gt;Any TEAE&lt;br&gt;MSB11022: 62.8%, USA-ADL: 56.3%, EU-ADL: 62.0%&lt;br&gt;Any serious AE&lt;br&gt;MSB11022: 2.6%,* USA-ADL: 0.0%, EU-ADL: 0.0%&lt;br&gt;*Were considered unrelated to the study drug</td>
</tr>
</tbody>
</table>

AE: adverse event; AUCinf: concentration time curve (AUC) from time 0 extrapolated to infinity; AUClast: concentration time curve (AUC) from time 0 extrapolated to last quantifiable concentration; CI: confidence interval; Cmax: maximum (peak) serum concentration; EU-ADL: European Union-sourced adalimumab; PK: pharmacokinetic; TEAE: treatment emergent adverse event; USA-ADL: United States of America-sourced adalimumab.
Table 3: Phase III clinical trials for each approved adalimumab biosimilar.

<table>
<thead>
<tr>
<th>Biosimilar</th>
<th>Trial phase</th>
<th>Population</th>
<th>N</th>
<th>Primary endpoint</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABP 501</td>
<td>Phase III</td>
<td>Moderate-to-severe active RA despite MTX</td>
<td>526</td>
<td>Therapeutic equivalence in ACR20 responses at Week 24; equivalence margin 0.738–1.355</td>
<td>EFFICACY: ACR20 response at Week 24 was 74.6% (ABP 501) and 72.4% (ADL); risk ratio of ACR20 (90% CI) between groups was 1.039 (0.954, 1.133) SAFETY: Any TEAE ABP 501: 50.0%, ADL: 54.6% Any serious AE ABP 501: 3.8%, ADL: 5.0% IMMUNOGENICITY Baseline ADAb: ABP 501: 1.9%; ADL: 2.3%; nAb: ABP 501: 0.0%, ADL: 0.0% Week 4, 12, or 26 ADAb: ABP 501: 38.3%; ADL: 38.2%; nAb: ABP 501: 9.1%, ADL: 11.1%</td>
</tr>
<tr>
<td></td>
<td>Phase III</td>
<td>Moderate-to-severe chronic plaque-type psoriasis</td>
<td>350</td>
<td>Therapeutic equivalence in PASI improvement at Week 16 (equivalence margin of ±15); PASI 50, PASI 75, PASI 90, and PASI 100 responses, sPGA response and mean change in affected BSA from baseline at Weeks 16, 32, and 50 after re-randomisation</td>
<td>EFFICACY: PASI percent improvement at Week 16 was 80.9% (ABP 501) and 83.1% (ADL) (least-square mean difference −2.18 [95% CI: −7.39 to 3.02]); after re-randomisation, PASI percent improvement at Week 32 was 87.6% (ABP 501/ABP 501), 88.2% (ADL/ADL), and 87.0% (ADL/ABP 501); at Week 50 was 87.2% (ABP 501/ABP 501), 88.1% (ADL/ADL), and 85.8% (ADL/ABP 501) sPGA at Week 16 was 66.4% (ABP 501/ABP 501), 73.4% (ADL/ADL), and 67.5% (ADL/ABP 501); at Week 32 was 66.4% (ABP 501/ABP 501), 72.2% (ADL/ADL), and 70.4% (ADL/ABP 501); and at Week 50 was 68.7% (ABP 501/ABP 501), 74.3% (ADL/ADL), and 69.6% (ADL/ABP 501) BSA affected at Week 16 of -19.3% (ABP 501/ABP 501), -24.2% (ADL/ADL), and -23.5% (ADL/ABP 501); Week 32 and 50 BSA results were similar to those at Week 16 and percentages for each group at all time points were comparable SAFETY: Week 16 Any TEAE ABP 501: 67.2%, ADL: 63.6% Any serious AE ABP 501: 3.4%, ADL: 2.9% Week 50 Any TEAE ABP 501/ABP 501: 71.1%, ADL/ADL: 65.8%, ADL/ABP 501: 70.1% Any serious AE ABP 501/ABP 501: 2.6%, ADL/ADL: 5.1%, ADL/ABP 501: 5.2% IMMUNOGENICITY Any time point throughout Week 52 ADAb: ABP 501/ABP 501: 68.4%, ADL/ADL 74.7%, ADL/ABP 501: 72.7%; nAb: ABP 501/ABP 501: 13.8%, ADL/ADL 20.3%, ADL/ABP 501: 24.7%</td>
</tr>
</tbody>
</table>
### Table 3 continued.

<table>
<thead>
<tr>
<th>Biosimilar</th>
<th>Trial phase</th>
<th>Population</th>
<th>N</th>
<th>Primary endpoint</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SB5</strong></td>
<td>Phase III&lt;sup&gt;24&lt;/sup&gt;</td>
<td>Moderate-to-severe active RA despite MTX</td>
<td>542</td>
<td>Therapeutic equivalence in ACR20 responses at Week 24; equivalence margins of ±15%</td>
<td><strong>EFFICACY</strong>&lt;br&gt;ACR20 response at Week 24 was 72.4% (SB5) and 72.2% (ADA); adjusted difference (SB5–ADA) was 0.1% (95% CI: -7.83–8.13%)&lt;br&gt;&lt;br&gt;<strong>SAFETY</strong>&lt;br&gt;Any TEAE SB5: 35.8%, ADA: 40.7%&lt;br&gt;Any serious AE SB5: 1.1%, ADA: 2.9%&lt;br&gt;&lt;br&gt;<strong>IMMUNOGENICITY</strong>&lt;br&gt;Up to Week 24&lt;br&gt;ADAb: SB5: 33.1%; ADA: 32.0%;&lt;br&gt;nAb: SB5: 16.5%, ADA: 16.0%&lt;br&gt;Week 24&lt;br&gt;ADAb: SB5: 32.4%, ADA: 31.4%;&lt;br&gt;nAb: SB5: 13.6%, ADA: 14.6%</td>
</tr>
<tr>
<td><strong>GP2017</strong></td>
<td>Phase III&lt;sup&gt;28&lt;/sup&gt;</td>
<td>Moderate-to-severe active RA despite MTX</td>
<td>353</td>
<td>Therapeutic equivalence in DAS28-CRP responses at Week 12; equivalence margin of ±0.6</td>
<td><strong>EFFICACY</strong>&lt;br&gt;Mean change from baseline at Week 12 in DAS28-CRP was -2.16% for GP2017 (n=140) and -2.18% for ADA (n=144) (∆=0.02; 95% CI: -0.24, 0.27)&lt;br&gt;&lt;br&gt;<strong>SAFETY</strong>&lt;br&gt;Any TEAE GP2017: 61.6%, ADA: 60.2%&lt;br&gt;Any serious AE GP2017: 1.7%, ADA: 1.7%&lt;br&gt;&lt;br&gt;<strong>IMMUNOGENICITY</strong>&lt;br&gt;Week 24&lt;br&gt;ADAb: GP2017: 21.8%, ADA: 24.4%;&lt;br&gt;nAb: GP2017: 75%, ADA: 73.2%</td>
</tr>
<tr>
<td></td>
<td>Phase III&lt;sup&gt;25&lt;/sup&gt;</td>
<td>Moderate-to-severe chronic plaque-type psoriasis</td>
<td>448</td>
<td>Therapeutic equivalence in PASI75 response rate at Week 16; equivalence margin of ±18%</td>
<td><strong>EFFICACY</strong>&lt;br&gt;PASI75 response at Week 16 was 58.1% (GP2017) and 55.9% (ADA); adjusted difference (GP2017–ADA) was 2.2% (95% CI: -6.79–11.10)&lt;br&gt;&lt;br&gt;<strong>SAFETY</strong>&lt;br&gt;Any TEAE GP2017: 61.3%; ADA: 64.9%&lt;br&gt;Any serious AE GP2017: 0.0%; ADA: 0.4%&lt;br&gt;&lt;br&gt;<strong>IMMUNOGENICITY</strong>&lt;br&gt;Baseline&lt;br&gt;ADAb: GP2017: 1.3%, ADA: 1.3%;&lt;br&gt;nAb: GP2017: 0.0%, ADA: 0.0%&lt;br&gt;Week 17&lt;br&gt;ADAb: GP2017: 25.7%, ADA: 26.7%;&lt;br&gt;nAb: GP2017: 95.8%, ADA: 97.7%</td>
</tr>
</tbody>
</table>
### Biosimilar | Trial phase | Population | N | Primary endpoint | Results |
|---|---|---|---|---|---|
| **BI 695501** | Phase III (VOLTAIRE-RA)\(^6\) | Moderate-to-severe active RA despite MTX | 645 | Therapeutic equivalence in ACR20 responses at Weeks 12 (equivalence margin: -12%–15%) and 24 (equivalence margin: ±15%) | **EFFICACY**  
ACR responses at Week 12: 67.0% (BI 695501) and 61.1% (ADL) (90% CI: -0.9–12.7); ACR responses at Week 24: 69.0% (BI 695501) and 64.5% (ADL) (95% CI: -3.4–12.5)  

**SAFETY**  
Any TEAE  
BI 695501/BI 695501: 19.1%, ADL/BI 695501: 19.2%, ADL/ADL: 22.9%  
Any serious AE  
BI 695501/BI 695501: 5.6%, ADL/BI 695501: 6.8%, ADL/ADL: 9.7%  

**IMMUNOGENICITY**  
Week 24  
ADAb: BI 695501: 1.70%, ADL: 3.28%;  
nAb: BI 695501: 1.4%, ADL: 2.5%  
Week 48  
ADAb: BI 695501: 47.4%, ADL: 53.0%;  
nAb: Frequencies up to Week 24 were also similar between the groups |
| **FKB327** | Phase III\(^7\) | Moderate-to-severe active RA despite MTX | 728 | Therapeutic equivalence in ACR20 responses at Weeks 24; equivalence margin ±13% | **EFFICACY**  
ACR20 responses at Week 24: 74.4% (FKB327) and 75.7% (ADL); (95% CI: -7.6–5.0)  

**SAFETY**  
Any TEAE  
FKB327: 55.5%, ADL: 61.6%  
Any serious AE  
FKB327: 4.1%, ADL: 5.2%  

**IMMUNOGENICITY**  
Baseline  
ADAb: FKB327: 3.7%, ADL: 5.3%;  
nAb: FKB327: 2.5%, ADL: 61.1%  
Week 24  
ADAb: FKB327: 62.0%, ADL: 59.4%;  
nAb: FKB327: 4.4%, ADL: 59.1% |
| **MSB11022** | Phase III\(^8\) | Moderate-to-severe chronic plaque-type psoriasis | 443 | Therapeutic equivalence in PASI75 response rate at Week 16; equivalence margin of ±18% | **EFFICACY**  
PASI75 response at Week 16 was 90.6% (MSB11022) and 91.7% (ADA); adjusted difference (MSB11022–ADA) was 1.0% (95% CI: -1.23–2.98)  

**SAFETY**  
Any TEAE  
MSB11022: 51.1%, ADA: 53.2%  
Any serious AE  
MSB11022: 3.6%, ADA: 2.7%  

**IMMUNOGENICITY**  
Week 24  
ADAb: MSB11022: 87.3%, ADL: 88.6%;  
nAb: MSB11022: 37.6%, ADL: 39.1% |

ACR20: American College of Rheumatology 20% improvement criteria; ADAb: antidrug antibody; ADL: adalimumab; AE: adverse event; BSA: body surface area; CI: confidence interval; DAS28-CRP: disease activity score-28 including high-sensitivity C-reactive protein; MTX: methotrexate; nAb: neutralising antibody; PASI: Psoriasis Area and Severity Index; RA: rheumatoid arthritis; sPGA: static Physician’s Global Assessment; TEAE: treatment emergent adverse event.
MSB11022 performed similarly to reference drug in Psoriasis Area and Severity Index (PASI) 75 response at Week 16 (primary endpoint) in a Phase III trial in plaque-type psoriasis, confirming biosimilarity. This biosimilar was recently assessed in a Phase III trial of RA patients but results were not available to this date. ABP 501 and GP2017 also had Phase III trials in plaque-type psoriasis, showing comparable results in primary (PASI percent improvement and PASI 75, respectively) and secondary endpoints at Week 16.

Despite being assessed in trials of patients with RA and psoriasis, approved adalimumab biosimilars were granted by the regulatory agencies with the remaining clinical indications of the originator drug (extrapolation of indications).

Safety

No new adverse events were found in Phase III clinical trials beyond those expected for the population and drug class, and the majority were classified as mild-to-moderate in severity.

The rate of treatment-emergent adverse events (TEAE) was similar in the biosimilar and reference drug groups, ranging from 19.1–61.6% for biosimilars (ABP 501: 50.0%, SB5: 35.8%, GP2017: 61.6%, BI 695501: 19.1%, FKB327: 55.5%, MSB11022: 58.0%) and 40.7–62.0% for reference adalimumab. The rate of severe adverse events was also similar in both groups, ranging from 1.1–5.6% for the biosimilar group (ABP 501: 3.8%, SB5: 1.1%, GP2017: 1.7%, BI 695501: 5.6%, FKB327: 4.1%, MSB11022: 3.6%) and 1.7–5.0% for the reference drug group.

Despite similar safety profiles, some minor differences are worth mentioning. For instance, ABP 501, BI 695501, and SB5 had fewer injection site reactions compared to reference adalimumab, which was considered not relevant and attributed to differences in excipients by regulatory agencies. BI 695501 showed increased incidence of analytical changes like anaemia (most in patients with low haemoglobin levels at baseline); bone fractures (but incidence within expected range in the general population); and positive screening for tuberculosis (no active cases). EMA accepted these events as rare and attributed to chance.

Immunogenicity

The use of a biologic agent can trigger an immune response, which may result in reduced efficacy, treatment failure, or adverse effects. Detailed immunogenicity evaluations are required for approval of biosimilars and the types of assays and sensitivity of detection are described in updated regulatory guidance documents. In the case of rheumatic diseases, 25 studies with immunogenicity data for 16 biosimilars or biosimilar candidates are published: 7 with adalimumab as the reference product (biosimilars BI 695501, SB5, ABP 501, FKB327, and MSB11022, and biosimilar candidates PF-06410293 and ZRC-3197).

Studies of adalimumab in both healthy volunteers and patients varied in methodology of antidrug antibodies (ADAb)/neutralising antibodies (nAb) detection, as well as study design and duration, meaning that comparisons between studies are not a reliable means to determine which biosimilar is more prone to elicit an immune response. Nevertheless, immunogenicity results of Phase III trials are summarised in Table 3.

The incidences of ADAb in adalimumab trials generally increased with trial duration (reaching a plateau after 12–24 weeks of treatment), a phenomenon that was not observed in trials of etanercept, rituximab, and their biosimilars. Typically, ADAb-positive individuals had lower drug concentrations and higher clearance rates compared with ADAb-negative individuals, with effects comparable between reference products and biosimilars. Overall, in adalimumab trials there is evidence that the formation of ADAb is associated with deterioration in certain pharmacodynamic parameters such as CRP or erythrocyte sedimentation rate and diminished clinical efficacy and safety, but the statistical significance of those differences was generally not examined in individual trials.

Cross-reactivity assessments show the ability of ADAb to bind both the reference and biosimilar products and have been reported in only four randomised control trials in rheumatic diseases, one of them with adalimumab and its biosimilar FKB327.

Biosimilars can be introduced into patients’ treatment regimens, which may affect immunogenicity. Available data for the biosimilars...
of adalimumab indicate that switching resulted in no changes in quantitative or qualitative immunogenicity (see below). Overall, the ranges of ADAb incidences in pivotal randomised control trials of reference products are lower than those reported in recent trials comparing them to their biosimilars, which may be a result of improvements in assay methodology (including sample handling, drug trough levels, validation techniques, sample storage, number of replicates), sensitivity (currently mandated by regulatory agencies), as well as patient disease status and the trial design employed.

Switch

All adalimumab biosimilars have information on at least one switch, except MSB11022. Their Phase III clinical trials were extended to a later period of evaluation where patients on the reference drug were re-randomised to switch to biosimilar or to remain on reference drug. These studies had on average a post-switch period of 28 weeks (ABP 501 [psoriasis]: Week 16 to 52; GP2017 [RA]: Week 24 to 48; BI 695501: Week 24 to 48; SB 5: Week 24 to 52; FKB327: Week 28 to 48). ACR20/50/70 response rates and mean change from baseline in DAS28-erythrocyte sedimentation rate were similar across the switched and the continuous groups. Also, there were no differences in the rate of treatment discontinuation between groups. In the study of SB5, radiographic results were also analysed. Radiographic progression was comparable between all treatment groups over the course of 52 weeks, and consistent with historical data for reference adalimumab. Whilst these studies assessed a single transition from reference to biosimilar drug, GP2017 had a Phase III trial performed in patients with chronic plaque-type psoriasis including a multiple-switch period. Patients achieving a ≥50% PASI improvement were re-randomised to maintain their originally assigned treatment or to receive either GP2017 or reference adalimumab during three alternating 6-week periods. Once again, no significant difference in efficacy, safety, or immunogenicity was found between switchers and non-switchers.

With regard to safety, the different clinical trials also showed similar results between switch and maintenance groups. The rate of TEAE was similar in these groups, ranging from 15.6–54.6% for switch groups (adalimumab to SB5: 37.6%)

PHARMACOECONOMICS OF ADALIMUMAB BIOSIMILARS

The bio-originator adalimumab has proven efficacy and safety in the treatment of rheumatic, ophthalmic, dermatological, and gastroenterological conditions. This therapeutic versatility has made adalimumab the top-selling drug worldwide since 2012. Naturally, expectations are high for the potential cost savings from adalimumab biosimilars and their role in the reduction of the economic burden of biotherapies.

A recently published article by Aladul et al. assessed the effect of the introduction of infliximab, etanercept, and adalimumab biosimilars in rheumatology and gastroenterology specialities on UK healthcare budget. The budget impact model built for adalimumab assumed a 33% price discount for the biosimilar drug in the first year and an annual 15% discount up to the fourth year, as well as price erosion of the reference drug reaching 50% at this latter time point. From 2017 to 2020, considering an annual...
growing market share of 10%, 35%, 60%, and 90%, savings due to Solymbic® (Amgen, USA), Amgevita® (Amgen, USA), and Imraldi® (Biogen, South Korea) are expected to reach £177 million and £91 million in rheumatic and inflammatory bowel diseases, respectively.40 Two other analyses were published as abstracts. The first used data from a USA claims-base and estimated annual combined savings of $6.1 million per 10,000 insured RA patients treated with infliximab or adalimumab biosimilars (assuming a 30% market share and 25% price discount).41 The second estimated combined savings over 1 year of €26 million, €351 million, and €98 million in France, Germany, and the UK, respectively, with the use of infliximab, etanercept, or adalimumab biosimilars in RA patients (assuming a 50% biosimilar quota and 30% price discount).42

Overall, budget impact analyses of adalimumab biosimilars are still scarce, especially when compared to infliximab and etanercept biosimilars. Based on what is known from these therapies, cost savings generated by adalimumab biosimilars will allow thousands of new patients to be treated every year (assuming these savings are re-invested) and will play an important role in the sustainability of healthcare systems worldwide.43

CONCLUSION

All currently approved adalimumab biosimilars have demonstrated equivalence to reference product in preclinical and clinical studies and have been rigorously scrutinised by regulatory agencies before approval. Further reassurance on the safety and efficacy of adalimumab biosimilars in clinically studied and extrapolated indications will come from mandatory long-term pharmacovigilance programmes established by the FDA and EMA, as well as real-world data from national patient registries. The worldwide success of bio-originator adalimumab will grant its biosimilars an economic impact that will surpass the one seen with infliximab, etanercept, or rituximab, further contributing to the treatment sustainability of patients with immune-mediated inflammatory conditions.

References


